Maximiliano Vasquez

This inventor holds 69 USPTO granted patents and 20 published patent applications, plus 8 CIPO patents and 22 EPO patents, primarily in Antibody Engineering (CPC class C07K). Top assignees: Adimab, LLC, Galaxy Biotech, LLC, Five Prime Therapeutics, Inc.. Active years: 2000-2026.

USPTO Granted Patents = 69 (Patent Applications = 20)

% Patents Active = 72.5

CIPO Patents = 8 (Patent Applications = 10)

EPO Patents = 22 (Patent Applications = 19)

Average Co-Inventor Count = 3.4

ph-index = 17

Forward Citations = 1,073(Granted Patents)

Forward Citations (Not Self Cited) = 990(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Palo Alto, CA (US) (2000 - 2024)
Lebanon, NH (US) (2020 - 2024)

Company Filing History:

Five Prime Therapeutics, Inc.

patents

4. 6 out of 392

Genetics Institute, Inc.

patents

5. 5 out of 1,072

Children's Medical Center Corporation

patents

6. 5 out of 1,265

Dana-Farber-Cancer Institute Inc.

patents

7. 5 out of 4,508

Eli Lilly and Company

Tracon Pharmaceuticals, Inc.

Washington University

Mochida Pharmaceutical Co., Ltd.

patents

15. 2 out of 19

Osaka Bioscience Institute

patents

16. 2 out of 29

Protein Design Labs, Inc.

patents

17. 1 out of 17

Facet Biotech Corporation

patents

18. 1 out of 5,020

Hoffmann-La Roche Inc.

patents

19. 1 out of 71

Progenics Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

Antibody Libraries

Monoclonal Antibodies

Synthetic Antibody Libraries

CSF1R Binding

TIM-3 Detection

Hepatocyte Growth Factor

Fibroblast Growth Factor

Endoglin Antibodies

Heterodimeric Antibodies

Rational Design

Potent Antibodies

Amyloid Beta Peptide

69 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679897 - MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 (2026-07-14),

2. 12018403 - Antibody libraries (2024-06-25),

3. 11891446 - Highly potent antibodies binding to death receptor 5 (2024-02-06),

4. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use (2023-01-03),

5. 11186646 - Antibodies that bind colony stimulating factor 1 receptor (CSF1R) (2021-11-30),

6. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3 (2021-10-26),

7. 11008568 - Rationally designed, synthetic antibody libraries and uses therefor (2021-05-18),

8. 11008383 - Rationally designed, synthetic antibody libraries and uses therefor (2021-05-18),

9. 10981990 - Antibody molecules to TIM-3 and uses thereof (2021-04-20),

10. 10941204 - Highly potent antibodies binding to death receptor 4 (2021-03-09),

11. 10889811 - Antibody libraries (2021-01-12),

12. 10787500 - Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species (2020-09-29),

13. 10689448 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2020-06-23),

14. 10562970 - Antibodies that bind colony stimulating factor 1 receptor (CSF1R) (2020-02-18),

15. 10472419 - Antibody molecules to TIM-3 and uses thereof (2019-11-12),

Certainly! Here is the article based on the information provided:

Title: Maximiliano Vasquez: Pioneering Innovator in Biotechnology

Introduction:

Maximiliano Vasquez, a visionary inventor based in Palo Alto, CA (US), has established himself as a trailblazer in the world of technology through his relentless pursuit of innovation and commitment to pushing boundaries.

Latest Patents:

With an impressive portfolio of 65 patents, Maximiliano's recent inventions include "Highly potent antibodies binding to death receptor 5" and "Anti-CD3-binding domains and antibodies comprising them," revolutionizing the field of biotechnology with groundbreaking advancements in pharmaceutical compositions and treatment methods.

Career Highlights:

Having worked with esteemed companies like Galaxy Biotech, LLC and Adimab, LLC, Maximiliano has honed his expertise and made significant contributions to the biotechnology sector. His innovative solutions have paved the way for novel approaches in T-cell activation and targeted cell killing potency.

Collaborations:

Throughout his career, Maximiliano has collaborated with accomplished professionals such as Man Sung Co and Kyung Jin Kim, fostering a culture of innovation and knowledge-sharing. These partnerships have led to the development of cutting-edge reagents and methodologies for identifying and characterizing CD3 binding domains.

Conclusion:

Maximiliano Vasquez's unwavering dedication to innovation and his groundbreaking inventions continue to inspire the next generation of inventors and entrepreneurs in the biotechnology industry. His visionary outlook and commitment to pushing the boundaries of what is possible make him a true luminary in the realm of technology.